Basic Information
| Drug ID | DDPD00458 |
|
| Drug Name | Imipramine | |
| Molecular Weight | 280.4073 | |
| Molecular Formula | C19H24N2 | |
| CAS Number | 50-49-7 | |
| SMILES | CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12 | |
| External Links | ||
| DRUGBANK | DB00458 | |
| T3DB | T3D2797 | |
| PubChem Compound | 3696 | |
| PDR | 1609 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Caco-2 Permeability | -4.85 | - | -4.85 | - | ADME Research, USCD |
| Log P | 4.8 | - | 4.8 | - | HANSCH,C ET AL. (1995) |
| Boiling Point | 160.0 | ℃ | 160 | ℃ | PhysProp |
| Melting Point | 174.5 | ℃ | 174-175 | ℃ | U.S. Patent 2,554,736. |
| Water Solubility | 18.2 | mg/L | 18.2 | mg/L | YALKOWSKY,SH & DANNENFELSER,RM 1992) |
| pKa | 9.4 | - | 9.4 | - | SANGSTER (1994) |
| Log S | -4.19 | - | -4.19 | - | ADME Research, USCD |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 95.0 | % | >95 | % | PO, oral; | DRUGBANK | |
| Bioavailability | 53.0 | % | 29-77 | % | DRUGBANK | Bioavailability | 42.0 | % | 42±3 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 200.0 | ng/ml | 200±137 | ng/ml | PO, oral; | The Pharmacological Basis of Therapeutics | |
| T Max | 4.0 | h | 2-6 | h | DRUGBANK | T Max | 4.0 | h | 2-6 | h | PO, oral; | The Pharmacological Basis of Therapeutics |
| Metabolic | 100.0 | % | ~100 | % | Liver metabolism; | DRUGBANK | Metabolic | 5.0 | % | 5 | % | Urinary excretion; PO, oral; | DRUGBANK |
| Clearance | 1.0 | L/h/kg | 1.0 | L/h/kg | Average clearance; | DRUGBANK | Clearance | 1.8 | L/h/kg | 1.8 | L/h/kg | Average clearance; | DRUGBANK | Clearance | 0.78 | L/h/kg | 13±1.7 | ml/min/kg | Children → ;Elderly ↓ ;Somking ↑ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.78 | L/h/kg | 13 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 15.0 | L/kg | 10-20.0 | L/kg | Apparent volume of distribution; | DRUGBANK | Volume of Distribution | 18.0 | L/kg | 18±2 | L/kg | Apparent volume of distribution; | Children → ;Elderly → ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 12.0 | L/kg | 12 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 12.0 | h | 12 | h | DRUGBANK | Half-life | 22.5 | h | 22.5 | h | DRUGBANK | Half-life | 16.0 | h | 16±1.3 | h | Children → ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 16.0 | h | 16 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 518.5 | mg/kg | 355-682 | mg/kg | PO, oral; Rattus, Rat; | T3DB | |
| Eliminate Route | 2.0 | % | <2 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 78.0 | % | 60-96 | % | plasma proteins; | DRUGBANK | Protein Binding | 90.1 | % | 90.1±1.4 | % | Elderly → ;HL,hyperlipoproteinemia ↑ ;myocardial infarction ↑ ;Burn ↑ ;rheumatoid arthritis → ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 2.5 | mg/kg/day | 2.5 | mg/kg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for children | 75.0 | mg/day | 75 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for children | 2.5 | mg/kg/day | 2.5 | mg/kg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for children | 50.0 | mg/day | 50 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for adolescents | 75.0 | mg/day | 75 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for adults | 200.0 | mg/day | 200 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for adults | 300.0 | mg/day | 300 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | PO, oral | Tofranil Tablets | imipramine hydrochloride | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1